基于速度的训练影响了帕金森病患者的功能,力量和力量
Caleb C Calaway1, Kylie J Martinez1, Ana Raquel Calzada Bichili1
1Laboratory of Neuromuscular Research and Active Aging, Department of Kinesiology and Sports Sciences, University of Miami, Coral Gables, Florida.
Journal of strength and conditioning research
|July 29, 2024
概括
基于速度的训练 (VBT) 在12周内显著改善了帕金森病 (PD) 患者的功能性表现,力量和力量. 这项研究证明了VBT.
科学领域:
- 运动生理学 运动生理学
- 神经康复 神经康复 神经康复
- 运动科学 运动科学 运动科学
背景情况:
- 帕金森病 (PD) 是一种影响运动功能的神经退行性疾病.
- 运动员通常使用基于速度的训练 (VBT),但其对PD的影响尚不清楚.
- 优化PD培训需要了解像VBT这样的新方法.
研究的目的:
- 研究VBT对PD患者的功能表现,力量和功率的影响.
- 为了比较两个VBT协议:10%和30%的速度损失值.
- 为了确定VBT是否会改变PD中的力-速度关系.
主要方法:
- 21名患有PD的参与者被随机分为10%或30%的VBT组.
- 在监督下,VBT在12周内每周进行3次.
- 评估包括步行速度,坐立测试,1RM和峰值功率 (CP和LP练习).
主要成果:
- 观察到最大步行速度,坐立表现和峰值功率的显著改善.
- 胸部压力和腿部压力练习都显著增加了力量 (1RM).
- 在峰值功率的力-速度关系中没有发现任何显著的变化.
结论:
- 基于速度的训练是提高PD患者的功能能力,力量和力量的有效方式.
- 10%和30%的速度损失协议都产生了积极的结果.
- 进一步的研究可以探索长期影响和PD的最佳VBT处方.
相关概念视频
Parkinson's Disease: Treatment
241
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
241
Parkinson's Disease: Overview
510
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
510


